12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept. Methods: Retrospective chart review of patients with nAMD previously treated with aflibercept for at least 12 months and subsequently...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Indian Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/IJO.IJO_627_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556772894015488 |
|---|---|
| author | Wajiha J Kheir Mahdi Hassoun Rola N Hamam Ziad Fayez Bashshur |
| author_facet | Wajiha J Kheir Mahdi Hassoun Rola N Hamam Ziad Fayez Bashshur |
| author_sort | Wajiha J Kheir |
| collection | DOAJ |
| description | Purpose:
To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Methods:
Retrospective chart review of patients with nAMD previously treated with aflibercept for at least 12 months and subsequently transitioned to ziv-aflibercept between January 1, 2019, and December 31, 2022, for a period of at least 12 months. Participants were identified, and their clinical and imaging information was extracted from our electronic health records system. Data on best corrected visual acuity (BCVA), intraocular pressure, injection intervals, central retinal thickness (CRT), volume cube presence of subretinal fluid (SRF), and intraretinal fluid (IRF) were obtained. Main outcome measures included changes in BCVA, injection intervals, CRT, SRF, and IRF before and after 12 months of ziv-aflibercept treatment.
Results:
Fifty-four eyes of 44 patients were included in the study. After 12 months of ziv-aflibercept treatment, BCVA decreased by 0.84 ETDRS letters (P = 0.424) compared to BCVA at the last visit prior to conversion from aflibercept. Injection intervals decreased by 1.18 weeks (P = 0.489). CRT significantly decreased by 15.66 µm (P = 0.005). SRF was present initially in 31.5% of eyes and decreased to 22.2% (P = 0.125). IRF was present initially in 42.6% of eyes and decreased to 35.2% (P = 0.219).
Conclusion:
Ziv-aflibercept demonstrated effectiveness in maintaining treatment outcomes in nAMD eyes previously treated with aflibercept. The treatment was well-tolerated with no reported adverse events. Ziv-aflibercept may be a cost-effective alternative and a potential solution to the financial burden associated with conventional anti-VEGF agents. |
| format | Article |
| id | doaj-art-1b07c8b49f6c47dab128c5ff38bc741e |
| institution | Kabale University |
| issn | 0301-4738 1998-3689 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Ophthalmology |
| spelling | doaj-art-1b07c8b49f6c47dab128c5ff38bc741e2025-01-07T06:28:38ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892025-01-0173Suppl 1S78S8210.4103/IJO.IJO_627_2412-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with afliberceptWajiha J KheirMahdi HassounRola N HamamZiad Fayez BashshurPurpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept. Methods: Retrospective chart review of patients with nAMD previously treated with aflibercept for at least 12 months and subsequently transitioned to ziv-aflibercept between January 1, 2019, and December 31, 2022, for a period of at least 12 months. Participants were identified, and their clinical and imaging information was extracted from our electronic health records system. Data on best corrected visual acuity (BCVA), intraocular pressure, injection intervals, central retinal thickness (CRT), volume cube presence of subretinal fluid (SRF), and intraretinal fluid (IRF) were obtained. Main outcome measures included changes in BCVA, injection intervals, CRT, SRF, and IRF before and after 12 months of ziv-aflibercept treatment. Results: Fifty-four eyes of 44 patients were included in the study. After 12 months of ziv-aflibercept treatment, BCVA decreased by 0.84 ETDRS letters (P = 0.424) compared to BCVA at the last visit prior to conversion from aflibercept. Injection intervals decreased by 1.18 weeks (P = 0.489). CRT significantly decreased by 15.66 µm (P = 0.005). SRF was present initially in 31.5% of eyes and decreased to 22.2% (P = 0.125). IRF was present initially in 42.6% of eyes and decreased to 35.2% (P = 0.219). Conclusion: Ziv-aflibercept demonstrated effectiveness in maintaining treatment outcomes in nAMD eyes previously treated with aflibercept. The treatment was well-tolerated with no reported adverse events. Ziv-aflibercept may be a cost-effective alternative and a potential solution to the financial burden associated with conventional anti-VEGF agents.https://journals.lww.com/10.4103/IJO.IJO_627_24afliberceptamdanti-vascular endothelial growth factorneovascular age-related macular degenerationziv-aflibercept |
| spellingShingle | Wajiha J Kheir Mahdi Hassoun Rola N Hamam Ziad Fayez Bashshur 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept Indian Journal of Ophthalmology aflibercept amd anti-vascular endothelial growth factor neovascular age-related macular degeneration ziv-aflibercept |
| title | 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept |
| title_full | 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept |
| title_fullStr | 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept |
| title_full_unstemmed | 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept |
| title_short | 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept |
| title_sort | 12 month outcomes of ziv aflibercept for neovascular age related macular degeneration in eyes previously treated with aflibercept |
| topic | aflibercept amd anti-vascular endothelial growth factor neovascular age-related macular degeneration ziv-aflibercept |
| url | https://journals.lww.com/10.4103/IJO.IJO_627_24 |
| work_keys_str_mv | AT wajihajkheir 12monthoutcomesofzivafliberceptforneovascularagerelatedmaculardegenerationineyespreviouslytreatedwithaflibercept AT mahdihassoun 12monthoutcomesofzivafliberceptforneovascularagerelatedmaculardegenerationineyespreviouslytreatedwithaflibercept AT rolanhamam 12monthoutcomesofzivafliberceptforneovascularagerelatedmaculardegenerationineyespreviouslytreatedwithaflibercept AT ziadfayezbashshur 12monthoutcomesofzivafliberceptforneovascularagerelatedmaculardegenerationineyespreviouslytreatedwithaflibercept |